Evidence map›Paper›PMID 40948744›Full record

ArticleFrontiers in immunology2025

Case Report: X-linked agammaglobulinemia with progressive neurodegeneration from immunological to neurological implications.

Xiaoyi Chen, Hao Gu, Yurong Piao, Yanli Ma, Yiran Zhao, Huawei Mao, Yuan Wang, Jie Deng

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoyi Chen *Department of Neurology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Hao Gu *Department of Immunology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yurong PiaoDepartment of Immunology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yanli MaDepartment of Neurology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Yiran ZhaoDepartment of Neurology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Huawei MaoDepartment of Immunology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yuan WangDepartment of Neurology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Jie DengDepartment of Neurology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: X-linked agammaglobulinemia (XLA) is a rare disorder associated with defective B-lymphocyte differentiation, also known as circulating B-cell deletion or deficiency, reduced levels of all serum immunoglobulin isoforms, and a lack of specific antibody production. XLA has rare neurological complications but has a refractory course and poor prognosis. Here, we report a case of XLA due to a Bruton tyrosine kinase gene variant with progressive neurodegeneration. Case description: We describe a boy with XLA who had recurrent infections since infancy and, after diagnosis was confirmed by genetic testing, was started on regular intravenous immunoglobulin at the age of 5 years. However, after a second episode of suspected meningitis at the age of 4.9 years, he developed motor and cognitive deterioration, becoming unable to sit, walk, eat or speak after 8 months, with frequent tremors and multiple seizures, and died of respiratory failure at the age of 7 years. Magnetic resonance imaging showed progressive whole brain atrophy. Combined with a mild lymphocytic inflammation of the cerebrospinal fluid, we suspected a chronic active infection of the central nervous system, but it was difficult to confirm our suspicion by serological testing due to the inability to produce neutralizing antibodies. Conclusions: Severe progressive neurodegeneration in XLA is rare. With this case we would like to discuss the difficulties in diagnosing infection in patients with XLA and the role of autoimmune mechanisms in the development of neurodegeneration.

Indexed as

AgammaglobulinemiaGenetic Diseases, X-LinkedNeurodegenerative DiseasesAgammaglobulinaemia Tyrosine KinaseBrainChildChild, PreschoolDisease ProgressionFatal OutcomeHumansImmunoglobulins, IntravenousMagnetic Resonance ImagingMaleAgammaglobulinaemia Tyrosine KinaseBTK protein, humanImmunoglobulins, IntravenousBtk genecentral nervous systemchronic active infectionprogressive neurodegenerationXLA

Identifiers

PMID40948744
PMCPMC12426244

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.